NAV

Dordaviprone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Dordaviprone
DrugBank Accession Number
DB14844
Background

Dordaviprone (ONC-201) is under investigation in clinical trial NCT03394027 (ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 386.499
Monoisotopic: 386.210661473
Chemical Formula
C24H26N4O
Synonyms
  • 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-one
  • 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one
External IDs
  • NSC-350625
  • ONC-201
  • ONC201
  • TIC-10
  • TIC10
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Dordaviprone is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when ONC-201 is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when ONC-201 is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when ONC-201 is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when ONC-201 is combined with Bupivacaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dordaviprone dihydrochloride53VG71J90J1638178-82-1Not applicable

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9U35A31JAI
CAS number
1616632-77-9
InChI Key
VLULRUCCHYVXOH-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
IUPAC Name
11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetraazatricyclo[7.4.0.0^{2,6}]trideca-1(9),5-dien-8-one
SMILES
CC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=O

References

General References
Not Available
Human Metabolome Database
HMDB0259080
ChemSpider
30904994
ChEMBL
CHEMBL4297310
ZINC
ZINC000169620396

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentDiffuse Intrinsic Pontine Gliomas (DIPG) / Diffuse Midline Glioma, H3 K27M-Mutant1
3RecruitingTreatmentGlioma / H3 K27M1
2Active Not RecruitingTreatmentBasal Ganglia Glioma / Diffuse Midline Glioma (DMG) / H3 K27M Glioma / High Grade Glioma: Glioblastoma (GBM) / Infratentorial Glioma / Thalamic Glioma1
2Active Not RecruitingTreatmentDiffuse Intrinsic Pontine Gliomas (DIPG) / Diffuse Midline Glioma, H3 K27M-Mutant / Recurrent Diffuse Intrinsic Pontine Glioma / Recurrent Diffuse Midline Glioma, H3 K27M-Mutant / Recurrent WHO Grade III Glioma / WHO Grade 3 Glioma1
2Active Not RecruitingTreatmentGlioma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.169 mg/mLALOGPS
logP2.45ALOGPS
logP3.05Chemaxon
logS-3.4ALOGPS
pKa (Strongest Basic)8.13Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area39.15 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity117.24 m3·mol-1Chemaxon
Polarizability42.91 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-b90e355b4a2d24e0fd4c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-311f497a97f98ce16903
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0059000000-991cefeaf917f1e806e5
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0019-0059000000-04938e8e1171959f5f10
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-007c-6789000000-e3b9331b6526ffe00ae9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-052u-3496000000-f2559131b269e82523fb
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 14:30 / Updated at December 13, 2022 10:46